THE USE OF STATINS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 DIABETES
Article PDF (Українська)

Keywords

chronic obstructive pulmonary disease, Type 2 diabetes mellitus, atorvastatin, treatment

Abstract views: 28
PDF Downloads: 11

How to Cite

Chernetska, N., & Dubyk, L. (2022). THE USE OF STATINS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 DIABETES. Medical Science of Ukraine (MSU), 18(4), 37-42. https://doi.org/10.32345/2664-4738.4.2022.06

Abstract

Relevancy. The combination of chronic obstructive pulmonary disease and type 2 diabetes is studied insufficiently. The incomplete treatment regimen hinders the solution to this problem by including statins in the complex treatment of patients with chronic obstructive pulmonary disease combined with type 2 diabetes mellitus.

Objective: to evaluate the effectiveness of including statins in the complex treatment of patients with chronic obstructive pulmonary disease secondary to type 2 diabetes mellitus.

Materials and methods. Examination of patients with chronic obstructive pulmonary disease (COPD), including 64 patients with concomitant type 2 diabetes, was conducted on the basis of the pulmonology department of the Chernivtsi Regional Clinical Hospital in 2016-2020. Patients were divided into two groups – the main and the control. Patients with COPD with concomitant type 2 diabetes in the main group (49 patients) were prescribed atorvastatin at a dose of 20-40 mg once a day. The control group (15 COPD patients with concomitant type 2 diabetes) received essential treatment without atorvastatin. Patients received basic therapy depending on the group of patients (A, B, C and D) and the prevalence of shortness of breath or the frequency of exacerbations, long-acting bronchodilators (long-acting β2-agonists and/or long-acting anticholinergic drugs). A separate group of patients received a combination of a long-acting β2-agonist with an inhaled glucocorticosteroid. Some patients were prescribed roflumilast and antibactereal drugs from the group of macrolides (azithromycin or erythromycin). In the presence of sputum, patients were prescribed mucolytic drugs (Lazolvan, ACC, carbocisteine, erdosteine). In case of exacerbation, patients received a short course glucocorticosteroids parenterally, antibacterial drugs (for infectious exacerbation), nebulizer therapy.               The effectiveness of therapy was evaluated after six months of treatment using the following diagnostic methods: clinical data (dyspnea, cough, sputum production - according to the BCSS scale; and shortness of breath, cough, sputum production and its color - according to the Paggiaro scale), the number of hospitalizations per year, the number emergency medical calls.               Mathematical processing of the obtained data was carried out using programs BioStat 2009 Professional, version 5.8.4.3 (AnalystSoft Inc.), SPSS (Statistical Package for Social Science Statistics) 16.0, Statistisa 10.0 StatSoft Inc., Microsoft Excel 2010. Before testing statistical hypotheses were determined coefficients of asymmetry and kurtosis using the Hahn-Shapiro-Wilkie test to analyze the normality of the distribution of values ​​in randomized samples.

Results. When analyzing clinical data in treatment dynamics with atorvastatin, it was found that according to the BCSS, shortness of breath in patients of the main group significantly decreased. Cough in COPD patients with concomitant type 2 diabetes treated with atorvastatin decreased by 25.3% at the end of treatment. A decrease in sputum production was observed in two groups of patients, and the changes were significant. Reduction of the frequency of exacerbations per year, the number of emergency calls, and the number of hospitalizations per year in the dynamics of atorvastatin treatment were also observed in COPD patients with concomitant type 2 diabetes.

Conclusion. the use of atorvastatin in the complex treatment of COPD patients with concomitant type 2 diabetes resulted in a decrease in the frequency of exacerbations per year, the number of emergency calls, and the number of hospital admissions per year.

https://doi.org/10.32345/2664-4738.4.2022.06
Article PDF (Українська)

References

Hanson C, Bowser EK, Frankenfield DC, Piemonte TA. Chronic Obstructive Pulmonary Disease: A 2019 Evidence Analysis Center Evidence-Based Practice Guideline. J Acad Nutr Diet. 2020 Feb 17; 121(1):139-165.e15. DOI: 10.1016/j.jand.2019.12.001.

View at:

Publisher Site: https://www.jandonline.org/article/S2212-2672(19)31696-X/fulltext

PubMed: https://pubmed.ncbi.nlm.nih.gov/32081589/

Walton GM, Stockley JA, Griffiths D, Sadhra CS, Purvis T, Sapey E. Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD? J Clin Med. 2016 Oct 11;5(10):89. DOI: 10.3390/jcm5100089.

View at:

Publisher Site: https://www.mdpi.com/2077-0383/5/10/89

PubMed: https://pubmed.ncbi.nlm.nih.gov/27727158/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086591/

Mroz RM, Lisowski P, Tycinska A, Bierla J, Trzeciak PZ, Minarowski L, Duszewska AM. Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. J. Physiol. Pharmacol. 2015; 66(1):111-28.

View at:

PubMed: https://pubmed.ncbi.nlm.nih.gov/25716971/

Zhang W, Zhang Y, Li CW, Jones P, Wang C, Fan Y. Effect of statins on COPD: a meta-analysis of randomized controlled trials. Chest. 2017; 152(6): 1159-68. DOI: 10.1016/j.chest.2017.08.015.

View at:

Publisher Site: https://journal.chestnet.org/article/S0012-3692(17)31432-0/fulltext

PubMed: https://pubmed.ncbi.nlm.nih.gov/28847550/

Korzh NV, Ostrovskyy MM. The implication of soluble intercellular adhesion molecule in the progression of COPD in overweight patients. Art of Medicine. 2021;1(17): 27-32. DOI: 10.21802/artm.2021.1.17.27.

View at:

Publisher Site: https://art-of-medicine.ifnmu.edu.ua/index.php/aom/article/view/603

Korzh NV, Ostrovskyy MM. Dynamics of systemic inflammatory markers in case of exacerbation of COPD (III degree of bronchial obstruction) in overweight patients with the optimization of management and treatment. The Pharma Innovation Journal. 2021;10(Issue 3):9-13.

View at:

Publisher Site: https://www.thepharmajournal.com/archives/?year=2021&vol=10&issue=3

URL: https://www.thepharmajournal.com/archives/2021/vol10issue3/PartA/10-3-68-312.pdf

Kuznetsova LP, Gopko ОF, Savchenko LV. Markers of systemic inflammation in COPD patients with obesity. Ukrainian Journal of Medicine, Biology and Sports = Ukrayinsʹkyy zhurnal medytsyny, biolohiyi ta sportu. 2020; 5(3):68-73. DOI: 10.26693/jmbs05.03.068

View at:

Publisher Site: https://jmbs.com.ua/archive/5/3/68

Gospodarsky I.Ya, Rega NI, Gospodarska HO. [Modern approaches to the therapy of patients with chronic obstructive pulmonary disease]. Ukrainian medical journal = Ukrayinsʹkyy medychnyy chasopys. 2021;6(146):45-47. [in Ukrainian]. DOI: 10.32471/umj.1680-3051.146.223818

View at:

Publisher Site: https://www.umj.com.ua/article/223818/suchasni-pidhodi-do-terapiyi-patsiyentiv-iz-hronichnim-obstruktivnim-zahvoryuvannyam-legen

URL: https://www.umj.com.ua/wp/wp-content/uploads/2021/12/5072.pdf?upload=

Savchenko LV, Kaidashev IP. [Alimentary obesity due to disordered eating behavior worsens the clinical course of chronic obstructive pulmonary disease]. Ukrainian pulmonology journal = Ukrayinsʹkyy pulʹmonolohichnyy zhurnal. 2017;2: 33-36. [in Ukrainian].

View at:

Publisher Site: http://www.ifp.kiev.ua/doc/journals/upj/17/pdf17-2/upj_2017_2_cont.htm

URL: http://www.ifp.kiev.ua/doc/journals/upj/17/pdf17-2/33.pdf

Savchenko LV, Kaidashev IP. [Lifestyle change improves quality of life and anthropometric indicators in patients with chronic obstructive pulmonary disease in combination with obesity]. The world of medicine and biology = Svit medytsyny ta biolohiyi. 2017;4(62):76-80. [in Ukrainian]. DOI: 10.26724/2079-8334-2017-4-62-76-80

View at:

Publisher Site: https://womab.com.ua/ua/smb-2017-04/6898

Savchenko L, Mykytiuk M, Cinato M, Tronchere H, Kunduzova O, Kaidashev I. IL-26 in the induced sputum is associated with the level of systemic inflammation, lung functions and body weight in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2018;13:2569-2575. DOI: 10.2147/COPD.S164833

View at:

Publisher Site: https://www.dovepress.com/il-26-in-the-induced-sputum-is-associated-with-the-level-of-systemic-i-peer-reviewed-fulltext-article-COPD

PubMed: https://pubmed.ncbi.nlm.nih.gov/30197513/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113910/

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.